Advances in cancer diagnosis, treatment, and supportive care have led to a growing population of adolescent and young adult (AYA) cancer survivors. Yet despite these advances, metastatic recurrence remains a leading cause of morbidity and mortality among patients with solid tumours, particularly in this age group.
A recent population-based study in California, USA, has provided new insights into the incidence and survival outcomes of metastatic recurrence in AYAs aged 15–39 years. Using linked data from the California Cancer Registry (CCR), the Department of Health Care Access and Information (HCAI), and Kaiser Permanente Northern California (KPNC), researchers analysed 48,406 patients diagnosed with invasive cancers between 2006 and 2018.
Key Findings
-
Incidence of metastatic disease: At diagnosis, 9.2% of patients had metastatic disease, while 9.5% of patients initially diagnosed with nonmetastatic disease subsequently experienced metastatic recurrence.
-
Cancer type and recurrence risk: Five-year cumulative incidence (CMI) of metastatic recurrence was highest among patients with sarcoma (24.5%), colorectal cancer (21.8%), cervical cancer (16.3%), and breast cancer (14.7%). Stage at diagnosis strongly influenced recurrence risk, with stage III disease consistently showing the highest rates.
-
Trends over time: The study found rising metastatic recurrence among patients with cervical cancer, particularly stage I disease (from 6.3% in 2006–2009 to 10.1% in 2015–2018). Conversely, metastatic recurrence decreased over time for stage III melanoma and colorectal cancer, potentially reflecting improvements in treatment and targeted therapies.
-
Survival outcomes: Overall survival was worse for AYAs with metastatic recurrence compared to those with metastatic disease at diagnosis for most cancer types, including breast, cervical, melanoma, sarcoma, and colorectal cancers. Notably, breast cancer patients with recurrence had nearly a threefold increased risk of death (hazard ratio 2.87; 95% CI, 2.52–3.27). In contrast, survival differences were not observed for testicular and thyroid cancers. Timing of recurrence also influenced prognosis, with later recurrence (≥24 months after diagnosis) associated with better survival in breast and cervical cancers.
Clinical Implications
This study underscores the substantial burden of metastatic disease in AYAs, with nearly 40% of patients with colorectal cancer and sarcoma—and approximately one-quarter of those with breast, cervical, and testicular cancers—experiencing metastatic disease or recurrence during a median follow-up of 6.7 years. These findings highlight the need for:
-
Improved monitoring and early detection strategies for metastatic recurrence in AYAs.
-
Personalized survivorship care that addresses the unique psychosocial and physical needs of this population.
-
Integration of registry data with electronic health records and claims data to better capture recurrence patterns and inform treatment planning.
Limitations
The study may underestimate the true incidence of metastatic recurrence because outpatient-only recurrences were not captured, and ICD coding may misclassify some cases. Survival comparisons could be influenced by lead-time bias due to later identification of recurrence in the HCAI database. Nevertheless, the high concordance with KPNC records supports the reliability of the findings.
Conclusion
Metastatic recurrence represents a significant clinical challenge for AYAs with cancer, varying by tumour type, stage, and timing of recurrence. These results emphasize the importance of continued surveillance, research, and tailored care strategies to improve outcomes for this growing survivor population.
Paper: Brunson, A., et al. Metastatic Recurrence Among Adolescents and Young Adults With Cancer. JAMA Oncol. doi:10.1001/jamaoncol.2025.4971 Published online November 26, 2025.
